Rankings
▼
Calendar
URGN Q1 2024 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena
URGN
UroGen Pharma Ltd.
$927M
Q1 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$19M
+9.2% YoY
Gross Profit
$17M
90.8% margin
Operating Income
-$26M
-137.1% margin
Net Income
-$32M
-171.9% margin
EPS (Diluted)
$-0.97
QoQ Revenue Growth
-20.2%
Cash Flow
Operating Cash Flow
-$32M
Free Cash Flow
-$32M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$201M
Total Liabilities
$241M
Stockholders' Equity
-$40M
Cash & Equivalents
$132M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$19M
$17M
+9.2%
Gross Profit
$17M
$15M
+14.2%
Operating Income
-$26M
-$22M
-16.8%
Net Income
-$32M
-$30M
-6.9%
Revenue Segments
Jelmyto
$19M
100%
← FY 2024
All Quarters
Q2 2024 →